Walleye Capital LLC purchased a new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 34,586 shares of the biotechnology company's stock, valued at approximately $428,000.
Other large investors have also modified their holdings of the company. Tcwp LLC bought a new stake in shares of Aurinia Pharmaceuticals in the 1st quarter valued at about $25,000. Geneos Wealth Management Inc. raised its holdings in shares of Aurinia Pharmaceuticals by 54.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 1,142 shares in the last quarter. Lazard Asset Management LLC raised its holdings in shares of Aurinia Pharmaceuticals by 164.7% in the 1st quarter. Lazard Asset Management LLC now owns 5,300 shares of the biotechnology company's stock valued at $65,000 after purchasing an additional 3,298 shares in the last quarter. Apollo Management Holdings L.P. bought a new stake in shares of Aurinia Pharmaceuticals in the 1st quarter valued at about $72,000. Finally, Great West Life Assurance Co. Can raised its holdings in shares of Aurinia Pharmaceuticals by 22.3% in the 1st quarter. Great West Life Assurance Co. Can now owns 6,533 shares of the biotechnology company's stock valued at $86,000 after purchasing an additional 1,192 shares in the last quarter. Institutional investors own 35.20% of the company's stock.
Get Aurinia Pharmaceuticals alerts:Analyst Upgrades and Downgrades
AUPH has been the subject of a number of analyst reports. Royal Bank of Canada decreased their target price on shares of Aurinia Pharmaceuticals from $22.00 to $18.00 and set an "outperform" rating for the company in a research report on Friday, August 5th. Oppenheimer decreased their price target on Aurinia Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating for the company in a research note on Monday, August 8th. Finally, HC Wainwright dropped their price target on Aurinia Pharmaceuticals from $30.00 to $26.00 and set a "buy" rating on the stock in a research note on Tuesday, August 9th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $20.40.
Aurinia Pharmaceuticals Stock Down 2.8 %
Aurinia Pharmaceuticals stock opened at $7.26 on Friday. The stock has a 50-day moving average price of $8.19 and a 200 day moving average price of $10.26. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -6.26 and a beta of 0.97. Aurinia Pharmaceuticals Inc. has a 52 week low of $6.28 and a 52 week high of $33.97.Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last released its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The business had revenue of $28.19 million during the quarter, compared to analysts' expectations of $27.07 million. Aurinia Pharmaceuticals had a negative net margin of 178.32% and a negative return on equity of 38.01%. During the same period last year, the company earned ($0.37) earnings per share. Research analysts anticipate that Aurinia Pharmaceuticals Inc. will post -0.85 EPS for the current fiscal year.
Aurinia Pharmaceuticals Company Profile
(Get Rating)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
Featured Stories
- Get a free copy of the StockNews.com research report on Aurinia Pharmaceuticals (AUPH)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP).
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.